XML 32 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share
 9 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
NOTE 3: EARNINGS PER SHARE
Components of basic and diluted earnings per share and excluded antidilutive potential common shares are as follows:
 
Three Months Ended June 30,
 
Nine Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
(in thousands, except per share amounts)
Net income from continuing operations attributable to EZCORP (A)
$
14,542

 
$
5,525

 
$
39,825

 
$
22,316

Income (loss) from discontinued operations, net of tax (B)
91

 
(265
)
 
(631
)
 
(1,868
)
Net income attributable to EZCORP (C)
$
14,633

 
$
5,260

 
$
39,194

 
$
20,448

 
 
 
 
 
 
 
 
Weighted-average outstanding shares of common stock (D)
54,464

 
54,295

 
54,453

 
54,247

Dilutive effect of restricted stock and 2024 Convertible Notes*
3,490

 
72

 
2,627

 
63

Weighted-average common stock and common stock equivalents (E)
57,954


54,367


57,080


54,310

 
 
 
 
 
 
 
 
Basic earnings per share attributable to EZCORP:
 
 
 
 
 
 
 
Continuing operations (A / D)
$
0.27

 
$
0.10

 
$
0.73

 
$
0.41

Discontinued operations (B / D)
—

 
—

 
(0.01
)
 
(0.03
)
Basic earnings per share (C / D)
$
0.27

 
$
0.10

 
$
0.72

 
$
0.38

 
 
 
 
 
 
 
 
Diluted earnings per share attributable to EZCORP:
 
 
 
 
 
 
 
Continuing operations (A / E)
$
0.25

 
$
0.10

 
$
0.70

 
$
0.41

Discontinued operations (B / E)
—

 
—

 
(0.01
)
 
(0.03
)
Diluted earnings per share (C / E)
$
0.25

 
$
0.10

 
$
0.69

 
$
0.38

 
 
 
 
 
 
 
 
Potential common shares excluded from the calculation of diluted earnings per share above, exclusive of the additional potential impact of the 2019 Convertible Notes Warrants, 2024 Convertible Notes and 2025 Convertible Notes*:
 
 
 
 
 
 
 
Restricted stock**
3,569

 
2,418

 
3,375

 
2,435


*
See Note 6 for discussion of the terms and conditions of these potential common shares and dilutive impact thereon.
**
Includes antidilutive share-based awards as well as performance-based and market conditioned share-based awards that are contingently issuable, but for which the condition for issuance has not been met as of the end of the reporting period.